DP
VTGN icon

Diadema Partners’s VistaGen Therapeutics VTGN Stock Holding History

Diadema Partners’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-106,500
Closed -$70.5K – 210
2025
Q4 		$70.5K Buy
106,500
+6,300
+6% +$22.8K 0.01% 139
2025
Q3 		$356K Buy
100,200
+100,000
+50,000% +$299K 0.09% 104
2025
Q2 		$400 Hold
200
– – ﹤0.01% 95
2025
Q1 		$500 Hold
200
– – ﹤0.01% 102
2024
Q4 		$590 Buy
+200
New +$563 ﹤0.01% 107

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Diadema Partners's VTGN Position: Q1 2026 in Review

Diadema Partners increased its VistaGen Therapeutics (VTGN) stake by 5.4% in Q1 2026, buying an estimated $3.3K and bringing the position to 105,428 shares worth $60.3K. The position accounts for 0.01% of the portfolio, ranked #133.

Diadema Partners first reported a position in VTGN in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.41M in Q1 2025. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

  • Diadema Partners held 105,428 shares of VistaGen Therapeutics worth $60.3K as of Q1 2026.
  • Diadema Partners bought 5,428 VistaGen Therapeutics shares in Q1 2026, an estimated $3.3K.
  • VistaGen Therapeutics made up 0.01% of Diadema Partners's portfolio in Q1 2026, its #133 holding.
  • Diadema Partners first reported a position in VistaGen Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Diadema Partners's VistaGen Therapeutics position peaked at $1.41M in Q1 2025.
  • 56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.